Immunitas Therapeutics is a startup. Brouky records 1 investor associated with the company.
Develops targeted therapeutics for complex diseases by applying novel single-cell analysis methods to identify and prioritize targets for drug development. The company is indicated as a clinical-stage developer focused on oncology and immunology.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.